Senhwa Biosciences, Inc. (TPEX:6492)
37.55
0.00 (0.00%)
Aug 19, 2026, 1:30 PM CST
Senhwa Biosciences Revenue
Senhwa Biosciences had revenue of 240.00K TWD in the quarter ending June 30, 2026, a decrease of -4.00%. This brings the company's revenue in the last twelve months to 1.05M, up 5.00% year-over-year. In the year 2025, Senhwa Biosciences had annual revenue of 1.07M with 7.00% growth.
Revenue (ttm)
1.05M
Revenue Growth
+5.00%
P/S Ratio
3,196.61
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.07M | 70.00K | 7.00% |
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | 1.00M | 450.00K | 81.82% |
| Dec 31, 2021 | 550.00K | -67.00K | -10.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apex Biotechnology | 1.87B |
| SYN-TECH Chem. & Pharm. | 1.27B |
| Sagittarius Life Science | 392.26M |
| BioGend Therapeutics | 236.58M |
| 3D Global Biotech | 206.74M |
| Formosa Pharmaceuticals | 52.59M |
| Shine-On BioMedical | 50.62M |
| OBI Pharma | 49.68M |
Senhwa Biosciences News
- 1 year ago - Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Benzinga